Company news
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) news
Protagonist Therapeutics, Inc. news releases on 6ix. Latest, Apr 4, 2023: Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares…
Press releases — page 3
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
April 3, 2023
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 14, 2023
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
March 14, 2023
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
March 6, 2023
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit
November 30, 2022
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting
November 2, 2022
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer
November 1, 2022
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 3, 2022
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
May 31, 2022
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
May 25, 2022
Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 3, 2022
Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
April 24, 2022
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
March 27, 2022
Protagonist Therapeutics Earns $25 Million Milestone Payment from Janssen Biotech for Dosing of Third Patient in Phase 2b Clinical Trial of PN-235 in Moderate-to-Severe Plaque Psoriasis
March 15, 2022
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
February 27, 2022
Protagonist Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
January 3, 2022
Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting
December 11, 2021
Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit
December 2, 2021
Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
December 1, 2021
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
November 14, 2021
Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
November 10, 2021
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting
November 3, 2021
Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 2, 2021
Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Collaboration with Janssen
October 25, 2021
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
October 11, 2021
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
October 10, 2021
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting
October 3, 2021
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program
September 16, 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
September 6, 2021
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma
August 9, 2021
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress
August 3, 2021
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists
July 27, 2021
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
June 17, 2021
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock
June 14, 2021
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock
June 13, 2021
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
June 10, 2021
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021
June 6, 2021
Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera
June 2, 2021
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232
May 23, 2021
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021
May 11, 2021
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 3, 2021
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting
April 26, 2021
Protagonist Announces Plans to Initiate a Global Phase 3 Study for Rusfertide in Polycythemia Vera Following Interactions with the U.S. Food & Drug Administration and the European Medicines Agency
March 21, 2021
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
March 9, 2021
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results
March 2, 2021
Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference
March 1, 2021
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
February 15, 2021